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See related article on page 918. In this issue of the Journal, Moizumi and colleagues1 from Sendai CityMedical Center and Tohoku University present a thought-provoking anal-ysis of their experience with what would be considered by most Westernsurgeons an iconoclastic approach to the management of intramural hema-toma of the ascending aorta (IMH). Applying an algorithm of expectant (Iwould not call it conservative) therapy to 33 patients with this condition
during a 9-year interval, these authors have acquired what is to my knowledge the
largest reported single-center experience with this uncommon entity. Their results
are excellent. They challenge us to rethink our approach to this condition.
In the authors’ series, only patients with cardiac tamponade, impending rupture
(described as hemodynamic instability or persistent pain), rupture, or progression of
the IMH underwent surgery. All others were treated medically with aggressive
antihypertensive therapy and bed rest. Nine of 33 patients underwent early surgery
with what can only be considered a highly acceptable mortality rate of 11%, given
that 5 of the 9 patients were in shock on admission and 3 underwent total arch
replacement. Early mortality in the medical group was also low at 5% (P not
significant). During the follow-up interval, 8 additional patients underwent surgery
for progression to frank dissection or for increasing aortic dilatation. Survivals at 1
and 2 years were similar in the two groups. The authors concluded that expectant
management with aggressive medical therapy and serial imaging studies, with
surgical intervention reserved for those with clinical or radiologic evidence of
progression, yields satisfactory results.
“It is hard to argue with success,” as one of my mentors is fond of saying, but do
these data indicate that medical management is the optimal approach to IMH? Do
they indicate equivalent—if not superior—results with medical therapy? Or do they
conversely demonstrate remarkably low surgical risk despite the systematic selec-
tion of only the sickest patients for surgery?
This study is not a comparison of treatment modalities. That would require
random assignment to two groups with a head-to-head comparison. To bicker over
surgery versus medicine would be to miss the mark. The issue here is much like the
debate regarding coronary angioplasty versus coronary artery bypass: it is the
validity and safety of a treatment algorithm that attempts triage of individual
patients to their most appropriate therapy, sparing unnecessary risk to those for
whom less aggressive management will suffice without withholding such therapy
from those who require surgery.
The central message here is not that medical management is preferable but rather
that, in selected cases, it is reasonable. These data serve to open the dialog. Previous
studies from Western countries have demonstrated rather consistently that IMHs
behave differently depending on location—ascending versus descending aorta. A
study of IMH reported in 1993 by Robbins and coworkers2 suggested a particularly
poor prognosis of the condition when it involves the ascending aorta, although the
experience was quite small. Of only 3 patients in whom the ascending aorta and arch
were involved, 1 survived hospitalization but had late progression to aneurysm
requiring surgery, a second had rupture in hospital, and the third underwent surgery
on an acute basis. These authors suggested that because of the poor prognosis
associated with this condition, early surgery should be considered for type A IMH.
This recommendation was widely adopted, and just 2 years thereafter O’Gara and
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DeSanctis3 argued that “distinctions between IMH and clas-
sic aortic dissection are clinically artificial and should be
abandoned so as not to delay appropriate treatment . . . pa-
tients with aortic IMH should be managed with the same
empirical guidelines that have been successfully adopted for
patients with classic dissection. Specifically, involvement of
the ascending aorta should prompt urgent surgical repair.”
Since then a number of other small series have supported
this notion. A meta-analysis of these studies recently re-
ported by Maraj and associates4 identified 81 cases of IMH
involving the ascending aorta. The mortality rate among
those treated surgically was 14%, whereas that among those
treated medically was 36%. The obvious conclusion is that
surgical management carries a lower risk than does medical
therapy.
The difficulty, of course, is that the conclusions the one
can draw from such retrospective studies are significantly
limited by the potential impact of selection bias. Were
moribund patients refused surgery, driving up the mortality
rate in the medical arm? Or were they sent to surgery in
desperation for lack of any other option? This problem
makes studies such as the one reported in this issue of the
Journal by Moizumi and colleagues1 vitally important in
defining the appropriate management of this condition.
It is now up to the reader to ask the practical questions—
does this approach make sense to me, and how can I use
these results to guide my practice? Can surgery be reason-
ably delayed in high-risk patients? What of low-risk pa-
tients? Of 24 patients initially managed medically, 6 pa-
tients ultimately had frank dissection develop, including 2
in whom the IMH initially resolved radiographically. Lo-
calized IMH is a very nearly curable disease, so is progres-
sion to generalized dissection with the chronic risk of an-
eurysmal dilatation of the remaining aorta tolerable? And is
a hospital stay measured in weeks acceptable, not only to
payors but to patients? In an era of next-day (if not same-
day) delivery of health care, will patients tolerate the sword
of Damocles or the surgeon’s scalpel?
It seems likely that IMH is a heterogeneous condition,
and its behavior may well depend on a variety of factors
including its relationship to other aortic conditions, such as
penetrating atherosclerotic ulcer, medial degeneration, or
underlying genetic factors affecting connective tissue integ-
rity. Indeed, the disparate results reported from Western
centers as compared with this and other centers in Japan
have suggested to some that the processes are fundamen-
tally different. Perhaps it is the genetic background that is
different. We are indebted to the authors and to the editor
for rekindling a controversy that stimulates us to think more
deeply about this uncommon but intriguing clinical entity
and for challenging us to make our practice evidence based
rather than anecdote driven.
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